Rinvecalinase alfa
Protein / enzyme therapeutic
Also known as DM199
Evidence outlook · registrational
Acute Ischemic Stroke: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2026-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02868996 NCT02868996 · Acute Ischemic Stroke Registry: NCT02868996 | 1 | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (30 days) 2017-03 | Safe and well tolerated by IV and SC routes, with no treatment-limiting adverse events. | not yet graded | link ↗ |
View 2 more trials
NCT05065216 NCT05065216 · Acute Ischemic Stroke Registry: NCT05065216 | 2/3 | Stroke Recovery (Day 90) 2026-12 | In progress: results expected 1 Dec 2026 | not yet graded | link ↗ |
ReMEDy1 NCT03290560 · Acute Ischemic Stroke Registry: NCT03290560 | 2 | Number of participants with treatment-related adverse events as assessed by CTCAE v4.3 (90 Days) 2020-01-23 | Primary safety outcome: serious adverse events in 43.5% on rinvecalinase alfa versus 31.1% on placebo. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Acute Ischemic Stroke: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rinvecalinase Alfa: this drug | Phase 2/3 | Protein / enzyme therapeutic | Tissue kallikrein-1 (KLK1) | not yet graded | No reviewed efficacy summary in this indication | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Reliable signal | NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants | |
| Edaravone (TTYP01) | Phase 3 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Apadamtase Alfa (Adzynma) | Phase 2 | Protein / enzyme therapeutic | ADAMTS13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4029 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7450 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8829 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rinvecalinase alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.